The Perils of Merging Pharmaceutical Quality Systems
This article was originally published in The Gold Sheet
Executive Summary
The mergers and acquisitions that drug makers are pursuing to obtain relief from today’s economic pressures could jeopardize quality assurance if not handled well, experts told a conference last month.
You may also be interested in...
Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
Boston Scientific Stung With Across-The-Board Corporate Warning Letter
FDA is targeting Boston Scientific with a rare and far-reaching enforcement measure that could prevent some of the firm's investigational products from receiving market approval in the near term
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.